Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback